However, PI3K inhibitors have not been approved by the FDA as monotherapy for patients with solid tumors so far, mainly due to concomitant MAPK or other bypass signaling pathway activation, reducing dependence on PI3K signaling for tumor growth and proliferation [21]. This evidence concerns the gene PIK3CA and neoplasm.